FDA advisory committee turns down Cell Therapeutics' lymphoma drug
This article was originally published in Scrip
Executive Summary
By a resounding 9-0 vote, the US FDA's oncologic drug advisory committee on 22 March recommended that the new drug application (NDA) from Cell Therapeutics Inc (CTI)